Rationale: Myoepithelial carcinoma mainly occurs in the salivary glands, but myoepithelial carcinoma of the lung is extremely rare neoplasm whose biological behavior and clinical course still remain to be fully elucidated. Although considered as low-grade carcinoma, these tumors have a high rate of recurrence or distant metastasis.
Introduction
Myoepithelial tumors are mainly occurred in the salivary glands and breast, which are extremely rare in the lung. The primary pulmonary myoepithelial carcinoma is considered to arise from the submucosal bronchial glands in lower respiratory tract, with only 11 known prior cases reported in the English literature to date. Myoepithelial carcinoma shows myoepithelial differentiation and lack a ductal component. [1] [2] [3] This report describes the case of a young Chinese female, presenting a primary myoepithelial carcinoma in the lung, and reviews the limited literature. Furthermore, we analyzed 56 thoracic cancer-related genes using the next-generation sequencing technology in this case.
Case report
A 24-year-old Chinese woman was admitted to our institution for the treatment of cough and hemoptysis. She denied other symptoms such as fever, fatigue, nausea, or weight loss. The patient had no history of cigarette smoking. She was diagnosed with tuberculosis at the local hospital but did not respond to antituberculosis medicines. The Eastern Cooperative Oncology Group (ECOG) performance status was 0, and her vital signs were normal with a heart rate of 98 bpm, respiratory rate of 20, blood pressure of 105/74 mm Hg, temperature of 36.8°C. Respiratory sounds were normal without any rales. Results of routine laboratory tests were normal, including blood routine examination, liver and kidney function, serum electrolyte levels, and blood coagulation function. Chest computed tomography (CT) indicated a 45Â 41 mm nodular shadow located in anterior segment of left upper lung (Fig. 1) . Preoperative biopsies were carried out and the histological examination indicated the diagnosis of salivary-type lung tumors. Real-time PCR assay for the detection of mycobacterium tuberculosis DNA was negative. The left upper lobectomy was therefore performed concomitantly.
The tumor was elastic-hard measuring 50 Â 50 mm, which involved phrenic nerve and visceral pleura, but no lymphatic or vascular invasion. The histological findings showed the tumor cells were continuous, which composed both of spindle cells and round cells with clear cytoplasm. These cells mainly have oval nuclei without significant macronuclei and multinucleated cells. Immunohistochemical staining showed the tumor cells were positive for P63, P40, CD34, PCK (partially), CK7 (partially), EMA (partially), Ki67/MIB-1 (40%) but negative for Desmin, SMA, S-100, Syna, CgA, NapsinA, and TTF-1 markers (Fig. 2) . There was no EWSR1 or SS18 gene translocation detected in the tumor tissue by FISH analysis. The diagnosis retained was pulmonary myoepithelial carcinoma, which was made after excluding epithelial-myoepithelial carcinoma, myoepthelioma, sarcomatoid carcinoma, neuroendocrine tumors, large cell lung cancer, and solitary fibrous tumor.
We also analyzed 56 thoracic cancer-related genes including EGFR, ALK, ERBB2, BRAF, MET, RET, ROS1, KRAS, and other protooncogene, tumor suppressor gene, genes related to drug metabolism by using the targeted next-generation sequencing. There was no mutation, translocation, or amplification in 56 important genes (Table 1) .
No chemotherapy or radiotherapy was carried out after the surgery. The patient is alive without any sign of recurrence at 12 months follow-up ( Fig. 1 ).
Discussion
Primary salivary gland-type lung tumors are rare and represent less than 1% of all lung tumors, which include mucoepidermoid carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma and other extremely rare variants. [4, 5] For treatment options of primary salivary gland-type lung tumors, complete surgical resection is associated with a longer overall survival time. Furthermore, postoperative radiotherapy could be recommended if the resection margin is proved to be positive. [4] In cases of advanced metastatic disease, systemic chemotherapy is also needed, but the standard chemotherapy regimen for primary salivary gland-type lung tumors remains to be fully elucidated. [5] Primary pulmonary myoepithelial carcinoma is thought to originate from submucosal bronchial glands in the lower respiratory tract, which has morphologic features similar to those of the salivary gland counterparts. Since it was first described in 1998, we have identified only 11 cases in the English literature. [1] [2] [3] [6] [7] [8] [9] [10] [11] [12] Because of the low incidence, relatively little is known about their precise pathological and clinical characters.
There are no markers or imaging characteristics which allow the preoperative diagnosis in pulmonary myoepithelial carcinoma. The diagnosis is mainly based on histopathological and immunohistochemical analysis. Morphologically, it is easily confused with other thoracic neoplasms. Primary pulmonary myoepithelial carcinoma and epithelial-myoepithelial carcinoma are distinguished by the absence or presence of ductal cells. Separation of pulmonary myoepithelial carcinoma from myoepithelioma is mainly based on cellular abnormalities, infiltrative growth or distant metastasis. [12] Clinical data from 12 patients are summarized in Table 2 . Most patients were male smokers aged more than 45 when diagnosis was confirmed. Most patients had preoperative biopsies of neoplasm, and subsequently underwent anatomic resections of the lesions. There were seldom local recurrences, but AKT1  ARAF  CCND1  CDK4  CDK6  CTNNB1  DDR2  ERBB3  ERBB4  FGF3  FGF4  FGF19  FGFR1  FGFR2  FGFR3  FLT3  HRAS  JAK1  JAK2  KDR  KIT  KRAS  MAP2K1  MTOR  MYC  NRAS  NRG1  NTRK1  NTRK2  NTRK3  PDGFRA  PIK3CA  PTCH1  RAF1  SMO  Tumor suppressor gene  ATM  BIM  BRCA1  BRCA2  CDKN2A  PTEN  RB1  STK11  TP53  TSC1 TSC2 Genes related to drug metabolism CYP2D6 DPYD UGT1A1 Higashiyama et al [6] 58/M Yes RUL, endobronchial 38 Sleeve bilobectomy (RUL, RML) Forearm and hip muscles 14 (died of other causes) Higashiyama et al [6] 58/M Yes LUL, endobronchial 60 LUL sleeve lobectomy Liver 60 (died of disease) Sekine et al [7] NA NA NA NA NA Yes NA Miura et al [8] 46/M NA Right main bronchus, endobronchial
65
Right pneumon-ectomy LLL 7 (alive with disease)
Masuya et al [9] 48/M Yes LLL, peripheral 15 LLL resection None 15 (alive without disease) Tanahashi et al [10] 76/M Yes LLL, peripheral 22 LLL wedge resection Brain 11 (dead of disease) Sarkaria et al [11] 63/F No RLL, pleural, peripheral 130 RLL wedge resection, excision Liver and diaphrag-ma 36 (alive with disease) Hysi et al [12] 60/F No LLL, peripheral 25 LLL, RLL resection RLL 10 (alive without disease) Rosen et al [1] 72/F Yes RUL, endobronchial 15 RUL wedge resection None 7 (alive without disease) Wei et al [2] 47/M Yes LLL, peripheral 65 LLL resection None 6 (alive without disease) Zhang et al [3] 51 Zhou et al. Medicine (2018) 97:9 www.md-journal.com some patients had metastatic disease. Follow-up for most patients was less than 5 years. Two patients were alive with disease, and 5 others were free of disease at relatively short follow-up intervals. Given the available data above, there are some unique characteristics for our case, including the only woman of childbearing age, as well as the seldom case with localized lesion in left upper lobe. Primary pulmonary myoepithelial carcinoma is relatively lowgrade malignant but show high rates of distant metastasis. Due to low incidence, no guideline on optimal therapeutic strategy is available. The surgical treatment is the only available therapeutic option. Further investigation will be necessary in order to clarify the relationship between chemotherapy/radiotherapy and clinical outcome.
To find the underlying molecular events and the potential therapeutic targets in pulmonary myoepithelial carcinoma, we analyzed 56 thoracic cancer-related genes by using the next-generation sequencing. Unfortunately, there was no mutation, translocation, or amplification in 56 important genes. More cases should be enrolled in the study to confirm the result, or whole-genome sequencing strategy should be applied to find the rare addicted oncogenes.
Conclusions
Primary pulmonary myoepithelial carcinoma should be included in the differential diagnosis of thoracic neoplasms. The surgical treatment is the only available therapeutic option. Given the rarity of these tumors, recommendations regarding chemotherapy or radiation are difficult to formulate. Individualized treatment is a promising clinical strategy for thoracic neoplasms, [13, 14] and the underlying molecular events should be investigated to find the potential therapeutic targets.
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